Abbott Laboratories Stock Price and Value Analysis

Abbott Laboratories (NYSE:ABT) in our automated value investing analysis, with the cash flow history and price comparison below.

Key Facts

Advertisement helps keep Trendshare free for most readers.

Hold-time calculator

Estimate how long you need to hold Abbott Laboratories to reach your target.

Target type

ABT Free Cash Flow Trend

Free Cash Flow trendline for ABT
Free Cash Flow trendline for Abbott Laboratories
CSV

Based on historical returns, we believe that Abbott Laboratories can grow its free cash at a rate of about 8%. That's positive!

AdvantagesDisadvantages
  • This company has an average dividend yield.
  • This company is making money at a decent rate.
  • This company is very stable.
  • This company has wild ups and downs.
  • This stock looks overpriced.

Inside the ABT Numbers

ABT Price
(Abbott Laboratories stock price per share)
$103.00
[?] ABT Fair Price
(based on intrinsic value)
$69.07
[?] ABT Safety Price (based on a variable margin of safety) $55.26
Try your own return

The fair price above uses a 10.1% discount rate, the long-run US stock return (10.1% geometric, 1926 to 2025, from Bessembinder's working paper, updated 2026-11-09), and 2.5% terminal growth. A higher rate suits a higher return target and gives a lower value.

Value per share:

[?] PE Ratio versus Sector 89% higher than other Healthcare stocks
[?] PE Ratio versus Industry 1221% higher than other Drug Manufacturers - General stocks
[?] Cash Yield 1.87%
[?] Free Cash Flow Jitter 48%
[?] Dividend Yield 2.43% (tax impact)
Shares Shorted 19,058,208

Insider Activity Summary

No open-market insider buys or sells are recorded for the last 12 months.

This stock has short interest! This means that people have shorted it.

Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.

As of the latest analysis, there are 19,058,208 shares shorted. With 1,721,757,784 shares available for purchase and an average trading volume over the past 10 trading days of 7,852,780, it would take at least 2.4 days for all of the short holders to cover their shorts.

Related guides: good annual rate of return · high-yield stocks · forecasting earnings growth

Free Cash Flow by Fiscal Year

How to read this: free cash flow in plain terms, free cash flow jitter.

Each year names the SEC filer that reported it, so a change of filer shows up here.

Fiscal yearSEC filer (CIK)Free cash flow (USD millions)
2007 1800 3,528
2008 1800 5,523
2009 1800 5,931
2010 1800 7,474
2011 1800 7,625
2012 1800 7,904
2013 1800 1,790
2014 1800 1,301
2015 1800 524
2016 1800 823
2017 1800 3,360
2018 1800 4,192
2019 1800 4,759
2020 1800 6,359
2021 1800 8,887
2022 1800 7,807
2023 1800 5,325
2024 1800 6,508
2025 1800 7,518

Download the yearly data as CSV.

Cash Conversion

How to read this: what free cash flow is, why earnings matter.

Over the 15 fiscal years from 2011 to 2025 with positive net income, operating cash flow totaled $102,858 million against net income of $72,054 million, or 1.43 times.

In 2025, operating cash flow was 1.47 times net income, compared with 1.63 times for the earliest three years (2011 to 2013).

In 2025, capital expenditures were $2,171 million, 22.7% of operating cash flow of $9,566 million, which leaves an estimated $7,395 million after capex. Across the 15 years with reported capex, it averaged 29.3% of operating cash flow. This uses that year's own capital expenditures, not the five-year average behind the free cash flow table, so the two can differ.

Fiscal yearNet income (USD millions)Operating cash flow (USD millions)Capital expenditures (USD millions)Operating cash flow / net income
2011 4,728 8,970 1,675 1.90
2012 5,963 9,314 1,985 1.56
2013 2,576 3,324 1,905 1.29
2014 2,284 3,675 5,290 1.61
2015 4,423 2,966 1,354 0.67
2016 1,400 3,203 1,366 2.29
2017 477 5,570 1,135 11.68
2018 2,368 6,300 1,394 2.66
2019 3,687 6,136 1,638 1.66
2020 4,495 7,901 2,177 1.76
2021 7,071 10,533 1,885 1.49
2022 6,933 9,581 1,777 1.38
2023 5,723 7,261 2,202 1.27
2024 13,402 8,558 2,207 0.64
2025 6,524 9,566 2,171 1.47

Where the Cash Went

How to read this: why companies buy back shares, dividend yield explained.

Over the 10 fiscal years from 2016 to 2025 with dividend or share repurchase facts, estimated free cash flow totaled $55,538 million. That estimate uses the average of up to five years of capital expenditures, not each year's own, so it is not a reported figure.

In the 10 of those years with dividend payment facts, dividends paid totaled $28,211 million, 50.8% of the estimated free cash flow of those years. Estimated free cash flow was at least the dividends paid in 9 of those 10 years.

In 9 of the 10 years, cash spent repurchasing shares was at least 5% of that year's estimated free cash flow, and in those years it totaled $11,390 million. Smaller amounts are left out of this sentence because they can be shares withheld to pay employees' taxes on stock awards.

In 2025, dividends and cash spent repurchasing shares together were $5,009 million, 66.6% of estimated free cash flow of $7,518 million.

Fiscal yearEstimated free cash flow (USD millions)Dividends paid (USD millions)Cash spent repurchasing shares (USD millions)Total returned (USD millions)Total as a percent of estimated free cash flow
2016 823 1,539 522 2,061 250.4%
2017 3,360 1,849 117 1,966 58.5%
2018 4,192 1,974 238 2,212 52.8%
2019 4,759 2,270 718 2,988 62.8%
2020 6,359 2,560 403 2,963 46.6%
2021 8,887 3,202 2,299 5,501 61.9%
2022 7,807 3,309 3,795 7,104 91.0%
2023 5,325 3,556 1,227 4,783 89.8%
2024 6,508 3,836 1,295 5,131 78.8%
2025 7,518 4,116 893 5,009 66.6%

Free cash flow here is an estimate: operating cash flow less the average of up to five years of capital expenditures. Cash spent repurchasing shares can include shares withheld to pay employees' taxes on stock awards. The entry n/a means the filings gave no usable figure, not that the amount was zero. Source: the company's annual reports to the SEC.

Revenue and Cash Margin

How to read this: earnings and margins.

Revenue was $25,914 million in 2007 and $44,328 million in 2025, a compound annual growth rate of 3.0% over 18 years.

Revenue rose 5.7% from 2024 to 2025.

Our estimated free cash flow was $7,518 million in 2025, 17.0% of revenue. In 2007 the estimated margin was 13.6%. This estimate charges each year with the average of up to five years of capital expenditures, so it is not the free cash flow the company reported.

Fiscal yearRevenue (USD millions)Estimated free cash flow (USD millions)Estimated free cash flow / revenue
2007 25,914 3,528 13.6%
2008 29,528 5,523 18.7%
2009 30,765 5,931 19.3%
2010 35,167 7,474 21.3%
2011 21,407 7,625 35.6%
2012 19,050 7,904 41.5%
2013 19,657 1,790 9.1%
2014 20,247 1,301 6.4%
2015 20,405 524 2.6%
2016 20,853 823 3.9%
2017 27,390 3,360 12.3%
2018 30,578 4,192 13.7%
2019 31,904 4,759 14.9%
2020 34,608 6,359 18.4%
2021 43,075 8,887 20.6%
2022 43,653 7,807 17.9%
2023 40,109 5,325 13.3%
2024 41,950 6,508 15.5%
2025 44,328 7,518 17.0%

Balance Sheet

How to read this: how debt and assets are compared, the current ratio.

In 2025, cash and equivalents were $8,522 million against total liabilities of $33,942 million, or 25.1% of total liabilities. Total liabilities include everything the company owes, not only borrowed money.

Total liabilities were 39.1% of total assets in 2025, compared with 55.1% in 2007, a decrease of 16.0 percentage points.

Stockholders equity was $52,771 million in 2025, compared with $17,824 million in 2007, a rise of 196.1%.

Based on our estimated free cash flow, cash flow return on invested capital (CROIC) was 12.2% in 2025. Invested capital here is total assets less cash and current liabilities.

Fiscal yearTotal assets (USD millions)Cash and equivalents (USD millions)Total liabilities (USD millions)Stockholders equity (USD millions)
2007 39,714 2,456 21,890 17,824
2008 42,419 4,112 24,901 17,519
2009 52,582 8,809 29,394 23,187
2010 60,574 3,648 37,809 22,765
2011 60,277 6,813 35,751 24,526
2012 67,235 10,802 40,422 26,813
2013 42,937 3,475 17,686 25,267
2014 41,207 4,063 19,568 21,639
2015 41,247 5,001 19,921 21,326
2016 52,666 18,620 31,949 20,717
2017 76,250 9,407 45,152 31,098
2018 67,173 3,844 36,451 30,722
2019 67,887 3,860 36,586 31,301
2020 72,548 6,838 39,545 33,003
2021 75,196 9,799 39,172 36,024
2022 74,438 9,882 37,533 36,905
2023 73,214 6,896 34,387 38,827
2024 81,414 7,616 33,513 47,901
2025 86,713 8,522 33,942 52,771

What the Price Implies

How to read this: discounted cash flow, intrinsic value.

At today's price of $103.00, our model's value equals that price if free cash flow grows an average of 16.5 percent a year over the 10 projection years. Our model assumes 8.0 percent a year for this stock, so the price implies growth of 16.5 percent, which is above the 8.0 percent our model assumes. This is the growth the price implies under our model, not a forecast of growth or a price target.

The table shows the same calculation at a price 20 percent lower and 20 percent higher than today's price, and the model's own growth rate at its fair price.

The model starts from the company's average free cash flow of $3,332 million, grows it over 10 years along the year-by-year growth path stored for this stock (the pace fades over the years, and the implied rate keeps that shape, so the rates here are 10-year averages), discounts it at 10.1 percent a year, adds a terminal value that grows 2.5 percent a year after year 10, adds the company's net worth, and divides by shares outstanding.

The baseline is the company's average free cash flow, and cyclical companies can mislead it.

CasePrice per shareAverage annual free cash flow growth
20 percent below the current price $82.40 12.0%
Current price $103.00 16.5%
20 percent above the current price $123.60 19.9%
Our model (stored fair price) $69.07 8.0%

Model assumptions: 10.1 percent discount rate, 2.5 percent terminal growth, 10 projection years. To try your own growth rate, use the intrinsic value calculator on this page. It uses a simpler single-rate model, so its results will not match the figures above exactly.

Price Versus Our Estimated Value

Every one of the 19 fiscal years we have for Abbott Laboratories under its current filer shows positive free cash flow.

At $103.00, the price is above our fair value estimate of $69.07 for Abbott Laboratories.

Abbott Laboratories's average free cash flow rose sharply, from $4,994 million in its earliest three years to $6,450 million in its latest three.

Free cash flow is volatile from year to year, with a variability measure of 48%.

Abbott Laboratories yields 2.43% in dividends.

These numbers change when new filings or prices arrive, so treat this page as a snapshot and check the company's own filings.

Compared With Its Sector and Industry

How to read this: the price to earnings ratio.

Its trailing P/E ratio is 89% above the average for stocks in the Healthcare sector.

Its trailing P/E ratio is 1221% above the average for stocks in the Drug Manufacturers - General industry.

A P/E ratio depends on trailing earnings, which one-time items can distort, so a lower P/E is not by itself evidence of value.

Closest Industry Peers

These are companies in the Drug Manufacturers - General industry, the ones closest in market capitalization to Abbott Laboratories, limited to companies whose pages we publish. The figures come from our latest data for each company.

CompanyMarket cap (USD millions)P/EDividend yieldCash yieldPrice versus our estimate
Abbott Laboratories (ABT) 178,390 38.4 2.4% 1.9% 49% above
Pfizer (PFE) 156,176 39.1 7.8% 11.6% 63% below
Bristol-Myers Squibb Company (BMY) 120,192 13.0 4.3% 1.2% 85% above
Regeneron Pharmaceuticals (REGN) 95,243 20.4 0.4% 0.5% 133% above
Teva Pharmaceutical Industries Limited (TEVA) 44,970 89.6 - 13.5% 47% below
Zoetis (ZTS) 32,144 13.5 2.6% - 865% above
United Therapeutics Corporation (UTHR) 23,625 20.9 - 1.5% 30% above

Industry labels are approximate, and companies in one industry can run quite different businesses, so a peer may not be a close match.

Ratios on different fiscal calendars are not strictly comparable, and a trailing P/E can be distorted by one-time items.

SEC Filer History

Every fiscal year on this page is reported by one SEC filer, CIK 1800.

Each figure on this page comes from that filer.

Risks to This Analysis

How to read this: understanding investment risk.

  • Free cash flow is volatile from year to year, so the estimates depend heavily on which years are included.
  • These figures are automated calculations from SEC filings and the recent price. They may contain errors, and they do not reflect lawsuits, management changes, or other events the filings do not show.

How This Page Is Made

Latest annual report used
Fiscal year 2025
Price and market data last refreshed
2026-11-20
Model assumptions last reviewed
2026-11-09

Company figures come from the annual reports (Form 10-K) that each company files with the SEC, read from the SEC EDGAR company facts data. The share price and other market data come from a market data provider.

Free cash flow here is operating cash flow minus capital spending. To keep one unusual year from swinging the result, each year is charged with the average of up to five years of capital spending, so the figure is an estimate and not the free cash flow a company reports.

The fair price is the present value of ten years of projected free cash flow plus a terminal value, discounted at 10.1 percent a year, the long-run return of US stocks, with 2.5 percent growth after year ten. The figures on this page are estimates, not advice.

This analysis covers US companies that file 10-K annual reports. Free cash flow describes banks, real estate investment trusts and funds poorly, so treat their figures with extra caution. In the cash returned and balance sheet tables, a value of zero is treated as a gap in the data, not as a real zero.

Read the filings yourself: ABT annual reports (10-K) on SEC EDGAR. To try your own growth rate, use the intrinsic value calculator on this page. Our editorial standards explain how Trendshare handles its sources and corrections.

Advertisement supports free stock analysis content.

Questions to Answer Before You Invest in ABT

Does Abbott Laboratories have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.

Worked example: ABT

This example shows how we apply the Trendshare checklist to ABT: earnings power, cash generation, valuation, and margin of safety.

We check: business quality, free cash flow, P/E, and margin of safety.

  1. Step 1 — Snapshot

    • Price: 103.00
    • Market cap: $178B
    • EPS: 2.68
  2. Step 2 — Valuation checks

    • P/E: 38.433
    • FCF yield: 1.9%
    • Date checked: Nov 20, 2026
  3. Step 3 — Margin of safety

    • Compare price to fair value and safety price.
    • Look for durable cash generation and reasonable leverage.
    • Decide if it passes your personal checklist.